favipiravir和molnupiravir在体外和体内对新型SARS-CoV-2变异的疗效

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Bulletin of Russian State Medical University Pub Date : 2022-12-01 DOI:10.24075/brsmu.2022.071
A. Siniavin, L. Russu, D. Vasina, EV Shidlovskaya, N. Kuznetsova, Vadim V. Guschin, A. Gintsburg
{"title":"favipiravir和molnupiravir在体外和体内对新型SARS-CoV-2变异的疗效","authors":"A. Siniavin, L. Russu, D. Vasina, EV Shidlovskaya, N. Kuznetsova, Vadim V. Guschin, A. Gintsburg","doi":"10.24075/brsmu.2022.071","DOIUrl":null,"url":null,"abstract":"The COVID-19 disease pandemic remains a significant global problem, resulting in hundreds of millions of cases and millions of deaths. The search for specific inhibitors of SARS-CoV-2 for the treatment of this infection remains relevant. Drugs such as Favipiravir and Molnupiravir, which exhibit specific antiviral activity against SARS-CoV-2, are already being used to treat patients. However, there is limited evidence of their effectiveness, especially against novel genetic variants of the COVID-19 pathogen. The aim of this study was to investigate the antiviral effect of these drugs using an in vitro experimental model of SARS-CoV-2 infection in Vero E6 cell culture and an animal model of infection using Syrian hamsters. It has been established that Molnupiravir has an inhibitory effect against variants of the SARS-CoV-2 with IC50 values from 16.51 to 7.88 μM in vitro, and reduces the infectious titer of the virus in the lungs of animals by ~1.5 Log10 in vivo, in while Favipiravir shows lower activity and severe toxicity. Dose selection and frequency of use remain unexplored.","PeriodicalId":9344,"journal":{"name":"Bulletin of Russian State Medical University","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of favipiravir and molnupiravir against novel SARS-CoV-2 variants in vitro and in vivo\",\"authors\":\"A. Siniavin, L. Russu, D. Vasina, EV Shidlovskaya, N. Kuznetsova, Vadim V. Guschin, A. Gintsburg\",\"doi\":\"10.24075/brsmu.2022.071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The COVID-19 disease pandemic remains a significant global problem, resulting in hundreds of millions of cases and millions of deaths. The search for specific inhibitors of SARS-CoV-2 for the treatment of this infection remains relevant. Drugs such as Favipiravir and Molnupiravir, which exhibit specific antiviral activity against SARS-CoV-2, are already being used to treat patients. However, there is limited evidence of their effectiveness, especially against novel genetic variants of the COVID-19 pathogen. The aim of this study was to investigate the antiviral effect of these drugs using an in vitro experimental model of SARS-CoV-2 infection in Vero E6 cell culture and an animal model of infection using Syrian hamsters. It has been established that Molnupiravir has an inhibitory effect against variants of the SARS-CoV-2 with IC50 values from 16.51 to 7.88 μM in vitro, and reduces the infectious titer of the virus in the lungs of animals by ~1.5 Log10 in vivo, in while Favipiravir shows lower activity and severe toxicity. Dose selection and frequency of use remain unexplored.\",\"PeriodicalId\":9344,\"journal\":{\"name\":\"Bulletin of Russian State Medical University\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin of Russian State Medical University\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24075/brsmu.2022.071\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Russian State Medical University","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24075/brsmu.2022.071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

新冠肺炎疫情仍然是一个重大的全球问题,导致数亿例病例和数百万人死亡。寻找治疗这种感染的严重急性呼吸系统综合征冠状病毒2型的特异性抑制剂仍然具有相关性。法维匹拉韦和莫努匹拉韦等药物对严重急性呼吸系统综合征冠状病毒2型具有特异性抗病毒活性,已被用于治疗患者。然而,关于其有效性的证据有限,尤其是针对新冠肺炎病原体的新基因变异。本研究的目的是使用Vero E6细胞培养中严重急性呼吸系统综合征冠状病毒2型感染的体外实验模型和使用叙利亚仓鼠的感染动物模型来研究这些药物的抗病毒作用。已经证实,莫努匹拉韦对体外IC50值为16.51至7.88μM的严重急性呼吸系统综合征冠状病毒2型变体具有抑制作用,并在体内将病毒在动物肺部的感染滴度降低约1.5 Log10,而法维匹拉韦表现出较低的活性和严重的毒性。剂量选择和使用频率尚未探索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy of favipiravir and molnupiravir against novel SARS-CoV-2 variants in vitro and in vivo
The COVID-19 disease pandemic remains a significant global problem, resulting in hundreds of millions of cases and millions of deaths. The search for specific inhibitors of SARS-CoV-2 for the treatment of this infection remains relevant. Drugs such as Favipiravir and Molnupiravir, which exhibit specific antiviral activity against SARS-CoV-2, are already being used to treat patients. However, there is limited evidence of their effectiveness, especially against novel genetic variants of the COVID-19 pathogen. The aim of this study was to investigate the antiviral effect of these drugs using an in vitro experimental model of SARS-CoV-2 infection in Vero E6 cell culture and an animal model of infection using Syrian hamsters. It has been established that Molnupiravir has an inhibitory effect against variants of the SARS-CoV-2 with IC50 values from 16.51 to 7.88 μM in vitro, and reduces the infectious titer of the virus in the lungs of animals by ~1.5 Log10 in vivo, in while Favipiravir shows lower activity and severe toxicity. Dose selection and frequency of use remain unexplored.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Bulletin of Russian State Medical University
Bulletin of Russian State Medical University MEDICINE, GENERAL & INTERNAL-
CiteScore
0.80
自引率
0.00%
发文量
59
期刊介绍: Bulletin of Russian State Medical University (Bulletin of RSMU, ISSN Print 2500–1094, ISSN Online 2542–1204) is a peer-reviewed medical journal of Pirogov Russian National Research Medical University (Moscow, Russia). The original language of the journal is Russian (Vestnik Rossiyskogo Gosudarstvennogo Meditsinskogo Universiteta, Vestnik RGMU, ISSN Print 2070–7320, ISSN Online 2070–7339). Founded in 1994, it is issued once every two months publishing articles on clinical medicine and medical and biological sciences, first of all oncology, neurobiology, allergy and immunology, medical genetics, medical microbiology and infectious diseases. Every issue is thematic. Deadlines for manuscript submission are announced in advance. The number of publications on topics in spite of the issue topic is limited. The journal accepts only original articles submitted by their authors, including articles that present methods and techniques, clinical cases and opinions. Authors must guarantee that their work has not been previously published elsewhere in whole or in part and in other languages and is not under consideration by another scientific journal. The journal publishes only one review per issue; the review is ordered by the editors.
期刊最新文献
Genetically encoded light-inducible sensor for nucleolar visualization Prefrontal cortex transcranial theta-burst stimulation frequency-dependent effects on cognitive functions Comparative bioinformatics analysis of antimicrobial resistance gene pool in the genomes of representatives of genus Corynebacterium Efficacy of the jawbone defect elimination Ischemic stroke with and without brachiocephalic artery dissections: results of comprehensive examination of patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1